No Data
Kojie Pharmacy-B (02171.HK) plans to hold a board of directors meeting on August 28 to approve its interim performance.
Kaiji Pharmaceutical-B (02171.HK) announced on August 15th that the board of directors meeting will be held on Wednesday, August 28th, 2024, to consider and approve the group's interim performance for the six months ending June 30th, 2024, as well as to handle other matters.
CARSGEN-B: DATE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
On June 28, Keji Pharmaceutical -B (02171.HK) spent HKD 720,000 to repurchase 150,000 shares.
On June 28th, Keji Pharmaceutical -B (02171.HK) announced that it had spent HKD 720,000 to repurchase 150,000 shares.
CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78%
Kangji Pharmaceutical (02171) under Hong Kong Stock Connect: the major shareholder has increased shareholding by 1.9 million shares, and the company has repurchased 3.98 million shares.
Jingu Finance News | Koji Pharmaceutical (02171) announced that the board of directors was informed by Yijie Biology that the Yijie concerted action group has purchased a total of 1.9035 million shares of the company's stock within this year until June 25, 2024 (after the close of trading), accounting for approximately 0.33% of the total issued shares. After increasing its shareholding, the Yijie concerted action group holds 217 million shares of the company's stock, accounting for approximately 37.78% of the total issued shares. In addition, as of the close of trading on June 25, 2024, the company has repurchased a total of 3.9855 million shares of its own stock, accounting for approximately 0.69% of the total issued shares. The funds used to repurchase the shares are from...
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% DropNo Data
